RACHELLE DOODY to Monoamine Oxidase Inhibitors
This is a "connection" page, showing publications RACHELLE DOODY has written about Monoamine Oxidase Inhibitors.
Connection Strength
0.061
-
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data. Parkinsonism Relat Disord. 2025 Mar; 132:107257.
Score: 0.061